Back

Comparison of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in myocardial infarction patients with type 2 diabetes

28 August 2023 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Treatment of acute coronary syndromes in clinical practice Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Jonathan Tjerkaski

Karolinska Institute, Stockholm (Sweden)

7 More presentations in this session

Presentation thumbnail
Effect of evolocumab on platelet function in patients with acute coronary syndromes. An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial
Doctor K. Koskinas (Bern, CH)
Abstract Slides Video
Presentation thumbnail
ARCANGELO: an observational, prospective study with acute coronary syndrome patients undergoing percutaneous coronary intervention who receive cangrelor transitioning to oral P2Y12 inhibitors
Doctor L. De Luca (Pavia, IT)
Abstract Slides
Presentation thumbnail
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis
Doctor S. Al Said (Boston, US)
Abstract Slides Video
Presentation thumbnail
SGLT2 inhibitor for secondary prevention in acute myocardial infarction patients with diabetes mellitus
Professor D. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
The effect of sodium-glucose co-transporter-2 inhibitors following anterior ST-segment elevation myocardial infarction
Doctor G. Incesu (Istanbul, TR)
Abstract Slides

Access the full session

Session thumbnail
Treatment of acute coronary syndromes in clinical practice

The Event

Event poster

ESC Congress 2023

28 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Presentation
SGLT-2 inhibitors are associated with lower rates of mortality following myocardial infarction in patients with type 2 diabetes - A SWEDEHEART observational study
thumbnail
Congress Presentation
Real-life use of novel glucose lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART-registry
thumbnail
Congress Presentation
Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources